Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association.
Recent Posts
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
By Andrew Powaleny | June 14, 2018
This week, the new era of medicine was brought to Capitol Hill in Washington, DC when 55 biopharmaceutical researchers from 20 PhRMA member companies held 79 meetings with members of Congress and...
Read More
Diversity of thought fuels next generation of breakthroughs
By Andrew Powaleny | June 7, 2018
This month, PhRMA is proud to join with our member companies to celebrate Lesbian, Gay, Bisexual and Transgender (LGBT) PRIDE Month.
Read More
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
By Andrew Powaleny | May 30, 2018
In the not too distant past, chemotherapy and radiation were once the only treatments for what remains the second leading cause of death in the United States – cancer. Although the death rates of...
Read More
Despite the current unprecedented pace of biopharmaceutical innovation, patients continue to face rising out-of-pocket costs and other barriers to care. Tomorrow, in partnership with The Atlantic,...
Read More
A new era in Alzheimer’s innovation
By Andrew Powaleny | April 19, 2018
After heart disease and cancer, Alzheimer’s disease and dementia are the leading cause of death for seniors, responsible for one out of every three deaths. Today, the disease devastates the minds...
Read More
New report shows over 500 medicines in development for neurological disorders
By Andrew Powaleny | April 18, 2018
Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the U.S. population....
Read More
Rare Disease Day: Unmet need inspires innovation
By Andrew Powaleny | February 28, 2018
Today, we celebrate Rare Disease Day to both reflect on the progress made toward conquering rare diseases and recognize the continued unmet medical need for these devastating, complex conditions.
Read More
New report shows 200 medicines in development for heart disease and stroke
By Andrew Powaleny | February 20, 2018
Cardiovascular disease, which includes heart disease and stroke, is the leading cause of death in the United States, accounting for one out of every three deaths. According to the American Heart...
Read More
ICYMI: Why 2017 medicine approvals matter
By Andrew Powaleny | January 12, 2018
This week, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) released its 2017 New Drug Therapy Approvals report. Last year marked an extraordinary...
Read More
ICYMI –Report highlights increasing prevalence for Alzheimer’s disease
By Andrew Powaleny | December 11, 2017
The number of Americans affected by Alzheimer’s disease (AD) continues to rise according to a new report.1 Researchers found that approximately 6.08 million Americans had Alzheimer’s or mild...
Read More
Medicare Monday (100)
340B Spotlight (35)
Cost & Consequence (0)
